Frontiers in Anti-Cancer Drug Discovery

Frontiers in Anti-Cancer Drug Discovery

Volume: 9

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Advancements in Anticancer Drug Delivery

Pp. 287-314 (28)

Hemant K.S. Yadav, Abrar E. Srouji, Alyazya Mohammed and Manar Dibi

Abstract

Cancer is considered one of the leading causes of death worldwide. Over the past few decades, researchers have worked reluctantly to discover anti-cancer agents that have saved millions of lives. However, the devastating statistics of increasing mortality due to cancer every year explain the continuous research in this field, to figure out newer agents and approaches for fighting cancer. This chapter will discuss some new drugs discovered which have the ability to effectively target cancer cells including, avelumab, neratinib, niraparib, durvalumab, nivolumab, Erleada and others along with their applications in treatment of various types of cancer like, skin, breast, ovarian, prostate, urothelial etc. Additionally, the chapter will discuss newly adopted strategies in cancer therapy through antibody-drug conjugates and the utilization of some already established non-cancer agents with a potential anti-cancer effect, such as NSAIDs, statins and antidiabetics. Moreover, some new combinations of known anticancer agents have shown additional benefits with significant results that will be further discussed in this chapter as well.

Keywords:

Apoptosis, Anti-Cancer Agents, Antibody-Drug Conjugates, Combination Therapy, Cell Proliferation, Overall Response Rate, Progression- Free Survival, Repurposing.

Affiliation:

Department of Pharmaceutics, RAK College of Pharmaceutical Sciences, RAK Medical & Health Sciences University, UAE.